Trial
NCT04303559
The Hemophilia Inhibitor Prevention Trial
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Margaret Ragni
Collaborators
Health Resources and Services Administration (HRSA)
Condition
Hemophilia A Without Inhibitor
Intervention
Eloctate Injectable Product
Why stopped
The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment, that the INHIBIT Trials be discontinued due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-11